Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases

Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development.

Year Invested: 2011
Location: Cambridge, Mass.

Recent News

November 15, 2018
Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy

October 30, 2018
Blueprint Medicines Reports Third Quarter 2018 Financial Results

October 29, 2018
Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International

Read More News

Associated Team Members

Alexis Borisy